EA202191485A1 - Синергетические композиции, содержащие (r)-2-(2-оксопирролидин-1-ил)бутанамид и (s)-2-(2-оксопирролидин-1-ил)бутанамид в нерацемическом соотношении - Google Patents

Синергетические композиции, содержащие (r)-2-(2-оксопирролидин-1-ил)бутанамид и (s)-2-(2-оксопирролидин-1-ил)бутанамид в нерацемическом соотношении

Info

Publication number
EA202191485A1
EA202191485A1 EA202191485A EA202191485A EA202191485A1 EA 202191485 A1 EA202191485 A1 EA 202191485A1 EA 202191485 A EA202191485 A EA 202191485A EA 202191485 A EA202191485 A EA 202191485A EA 202191485 A1 EA202191485 A1 EA 202191485A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxopyrrolidin
butanamide
nonracemic
ratio
compositions containing
Prior art date
Application number
EA202191485A
Other languages
English (en)
Inventor
Карло Фарина
Михаэль Шерц
Карла Гелардини
Лоренцо Ди Чезаре Манелли
Original Assignee
Метис Фармасьютиклз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метис Фармасьютиклз Аг filed Critical Метис Фармасьютиклз Аг
Publication of EA202191485A1 publication Critical patent/EA202191485A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

В заявке описаны композиция, содержащая энантиомеры 2-(2-оксопирролидин-1-ил)бутанамида и их фармацевтически приемлемые сольваты или совместные кристаллы в определенном соотношении, фармацевтическая композиция, содержащая указанную композицию, ее применение в качестве лекарственного средства и применение композиций или фармацевтических композиций, предлагаемых в настоящем изобретении, для лечения и/или предупреждения заболевания или нарушения, обычно и предпочтительно выбранного из числа следующих: связанные с припадками нарушения, периферическая сенсорная невропатия, предпочтительно периферическая невропатическая боль; припадок; депрессия или нарушения познавательной способности.
EA202191485A 2018-12-04 2019-12-04 Синергетические композиции, содержащие (r)-2-(2-оксопирролидин-1-ил)бутанамид и (s)-2-(2-оксопирролидин-1-ил)бутанамид в нерацемическом соотношении EA202191485A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18210106 2018-12-04
PCT/EP2019/083594 WO2020115093A1 (en) 2018-12-04 2019-12-04 Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Publications (1)

Publication Number Publication Date
EA202191485A1 true EA202191485A1 (ru) 2021-08-30

Family

ID=64604549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191485A EA202191485A1 (ru) 2018-12-04 2019-12-04 Синергетические композиции, содержащие (r)-2-(2-оксопирролидин-1-ил)бутанамид и (s)-2-(2-оксопирролидин-1-ил)бутанамид в нерацемическом соотношении

Country Status (20)

Country Link
US (1) US20220047548A1 (ru)
EP (1) EP3890833B1 (ru)
JP (1) JP2022510363A (ru)
KR (1) KR20210099567A (ru)
CN (1) CN113164767A (ru)
AU (1) AU2019391309A1 (ru)
BR (1) BR112021010739A2 (ru)
CA (1) CA3117350A1 (ru)
CO (1) CO2021007055A2 (ru)
EA (1) EA202191485A1 (ru)
EC (1) ECSP21040300A (ru)
ES (1) ES2953785T3 (ru)
HU (1) HUE062575T2 (ru)
IL (1) IL283441A (ru)
JO (1) JOP20210082A1 (ru)
MX (1) MX2021006243A (ru)
PL (1) PL3890833T3 (ru)
SG (1) SG11202105863PA (ru)
WO (1) WO2020115093A1 (ru)
ZA (1) ZA202102701B (ru)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2657571A1 (en) * 2006-07-25 2008-01-31 Zach System S.P.A. Process for the preparation of levetiracetam
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
EP2098526B1 (en) 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
EP2671858A1 (en) * 2012-06-08 2013-12-11 Université Catholique De Louvain Process for chiral resolution of etiracetam
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
HUE062575T2 (hu) 2023-11-28
CN113164767A (zh) 2021-07-23
KR20210099567A (ko) 2021-08-12
SG11202105863PA (en) 2021-07-29
EP3890833B1 (en) 2023-06-07
IL283441A (en) 2021-07-29
PL3890833T3 (pl) 2023-09-18
EP3890833C0 (en) 2023-06-07
AU2019391309A1 (en) 2021-05-20
BR112021010739A2 (pt) 2021-08-24
ECSP21040300A (es) 2021-07-30
WO2020115093A1 (en) 2020-06-11
ZA202102701B (en) 2023-10-25
CO2021007055A2 (es) 2021-06-10
US20220047548A1 (en) 2022-02-17
JOP20210082A1 (ar) 2023-01-30
EP3890833A1 (en) 2021-10-13
MX2021006243A (es) 2021-08-11
CA3117350A1 (en) 2020-06-11
ES2953785T3 (es) 2023-11-16
JP2022510363A (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2024010300A (es) Composiciones farmaceuticas que contienen anticuerpos anti-beta-amiloides.
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
GEP20247644B (en) Inhibitors of adrenoreceptor adrac2
EA201991898A1 (ru) Двойные ингибиторы magl и faah
MX2021007142A (es) Compuestos organicos.
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
PH12019502580B1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
EA202191485A1 (ru) Синергетические композиции, содержащие (r)-2-(2-оксопирролидин-1-ил)бутанамид и (s)-2-(2-оксопирролидин-1-ил)бутанамид в нерацемическом соотношении
EA202091885A1 (ru) Формы сокристаллов аналога новобиоцина и пролина
EA202191486A1 (ru) СИНЕРГЕТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ R-2-(ЗАМЕЩЕННЫЙ СУЛЬФОНИЛ)ГЕКСАГИДРОПИРРОЛО[1,2-а]ПИРАЗИН-6(2H)ОНЫ И S-2-(ЗАМЕЩЕННЫЙ СУЛЬФОНИЛ)ГЕКСАГИДРОПИРРОЛО[1,2-а]ПИРАЗИН-6(2H)ОНЫ В НЕРАЦЕМИЧЕСКОМ СООТНОШЕНИИ
MX2020000834A (es) Derivado de adamantilmetilamina y uso del mismo como producto farmaceutico.
EA202090682A1 (ru) Модуляторы кальциевых каналов, активируемых высвобождением кальция, для лечения гематологических и солидных раковых заболеваний